Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege

Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege
复制标题

DOI:
10.1158/0008-5472.can-06-0261
复制
发表时间:
2006-06-01
期刊:
影响因子:
11.2
通讯作者:
Ueda, Ryuzo
Ueda, Ryuzo
中科院分区:
医学1区
文献类型:
--
作者:
Ishida, Takashi;Ishii, Toshihiko;Ueda, Ryuzo

文献摘要

被引文献

相似文献

霍奇金淋巴瘤(HL)的特征是在丰富的炎性细胞背景中存在少量的肿瘤细胞,但大量的非肿瘤细胞对HL发病机制的贡献知之甚少。我们发现,HL细胞诱导的迁移性CD 4(+)细胞对T细胞受体刺激反应迟钝,并抑制了自体环境中效应CD 4(+)T细胞的活化/增殖。我们进一步表明,HL细胞在受影响的淋巴结被大量的淋巴细胞表达CC趋化因子受体4(CCR 4)和FOXP 3。这些结果表明,HL细胞诱导的迁移细胞具有调节性T(Treg)细胞的功能,从而为肿瘤细胞逃离宿主免疫系统创造了有利的环境。此外,我们发现嵌合抗CCR 4单克隆抗体(mAb)可以在体外清除CCR 4(+)T细胞,并抑制CD 4(+)CD 25(+)T细胞的迁移。认识到CCR 4(+)Treg细胞在HL发病机制中的重要性将允许合理设计更有效的治疗,例如使用抗CCR 4 mAb,以克服CCR 4(+)Treg细胞对宿主对肿瘤细胞的免疫应答的抑制作用。
Hodgkin lymphoma (HL) is characterized by the presence of a small number of tumor cells in a rich background of inflammatory cells, but the contribution of the abundant nontumor cells to HL pathogenesis is poorly understood. We showed that migratory CD4(+) cells induced by HL cells were hyporesponsive to T-cell receptor stimulation and suppressed the activation/proliferation of the effector CD4(+) T cells in an autologous setting. We further showed that HL cells in the affected lymph nodes were surrounded by a large number of lymphocytes expressing both CC chemokine receptor 4 (CCR4) and FOXP3. These findings indicate that the migratory cells induced by HL cells function as regulatory T (Treg) cells so that these cells create a favorable environment for the tumor cells to escape from host immune system. In addition, we showed that a chimeric anti-CCR4 monoclonal antibody (mAb) could deplete CCR4(+) T cells and inhibit the migration of CD4(+)CD25(+) T cells in vitro. Recognition of the importance of CCR4(+) Treg cells in the pathogenesis of HL will allow rational design of more effective treatments, such as use of an anti-CCR4 mAb, to overcome the suppressive effect of CCR4(+) Treg cells on the host immune response to tumor cells.